RESUMEN
OBJECTIVE: We assessed survival, hospital length of stay (LOS), and costs of medical care for infants with lethal congenital malformations, and also examined the relationship between medical and surgical therapies and survival. STUDY DESIGN: Retrospective cohort study including infants born 1998-2009 with lethal congenital malformations, identified using a longitudinally linked maternal/infant database. RESULTS: The cohort included 786 infants: trisomy 18 (T18, n = 350), trisomy 13 (T13, n = 206), anencephaly (n = 125), bilateral renal agenesis (n = 53), thanatophoric dysplasia/achondrogenesis/lethal osteogenesis imperfecta (n = 38), and infants > 1 of the birth defects (n = 14). Compared to infants without birth defects, infants with T18, T13, bilateral renal agenesis, and skeletal dysplasias had longer survival rates, higher inpatient medical costs, and longer LOS. CONCLUSION: Care practices and survival have changed over time for infants with T18, T13, bilateral renal agenesis, and skeletal dysplasias. This information will be useful for clinicians in counseling families and in shaping goals of care prenatally and postnatally.
Asunto(s)
Anomalías Congénitas/economía , Anomalías Congénitas/mortalidad , Anomalías Congénitas/terapia , Costos de la Atención en Salud/estadística & datos numéricos , Aceptación de la Atención de Salud/estadística & datos numéricos , Bases de Datos Factuales , Femenino , Florida/epidemiología , Humanos , Lactante , Recién Nacido , Estimación de Kaplan-Meier , Riñón/anomalías , Enfermedades Renales/congénito , Enfermedades Renales/economía , Enfermedades Renales/mortalidad , Tiempo de Internación/economía , Masculino , Anomalías Musculoesqueléticas/economía , Anomalías Musculoesqueléticas/mortalidad , Estudios Retrospectivos , Tasa de Supervivencia , Síndrome de la Trisomía 13/economía , Síndrome de la Trisomía 13/mortalidad , Síndrome de la Trisomía 18/economía , Síndrome de la Trisomía 18/mortalidadRESUMEN
The objective of this study was to implement and evaluate a quality improvement project (the golden hour pathway [GHP]) aimed at improving the quality and efficiency of care delivered to extremely low birth weight (ELBW) infants <28 weeks gestation and/or <1000 g birth weight during the first hour of life. Process improvement and patient data collected during the quality improvement cycles were compared with retrospective data for ELBW infants admitted to the study neonatal intensive care unit during the 2 years prior to GHP implementation. GHP implementation resulted in improvements compared with past internal performance in time to surfactant administration, time to administration of dextrose and amino acids, body temperature at admission, odds of developing chronic lung disease, and odds of developing retinopathy of prematurity. A standardized interdisciplinary approach to the care of ELBW infants in the first hour of life can lead to more efficient care delivery and contribute to improved outcomes.
Asunto(s)
Recién Nacido de muy Bajo Peso , Unidades de Cuidado Intensivo Neonatal/organización & administración , Mejoramiento de la Calidad/organización & administración , Aminoácidos/administración & dosificación , Temperatura Corporal , Edad Gestacional , Glucosa/administración & dosificación , Humanos , Recién Nacido , Unidades de Cuidado Intensivo Neonatal/normas , Surfactantes Pulmonares/administración & dosificación , Mejoramiento de la Calidad/normas , Estudios Retrospectivos , Medición de Riesgo , Factores de TiempoRESUMEN
BACKGROUND: An increasing number of infants are diagnosed with neonatal abstinence syndrome (NAS). The study's primary objectives were to describe an academic medical center's level IV neonatal ICU's (NICU's) comprehensive outpatient NAS management effort, measure guideline compliance, and assess its safety. Secondary objectives were to describe the duration and cumulative methadone exposure, and to improve parent and provider knowledge of NAS. METHODS: The study included 22 infants having a gestational age of 35-41 weeks, diagnosed with NAS, and discharged for outpatient methadone management. Discharges spanned 10 months and included 3 improvement periods. The outpatient program includes comprehensive discharge planning, a focused electronic health record (EHR) template, management guidelines, and parent and provider education. RESULTS: Providers complied with using the outpatient management guideline and EHR template, and assessed weight, NAS symptoms, and methadone dose during appointments. Two infants required NAS-related hospital readmission in the study period. From improvement period 1 to period 3 there was no difference in total outpatient days on methadone (58, 53, 74 days, respectively) or cumulative methadone dose (2.7, 2.6, 3.1mg/kg, respectively). A downward trend pattern in cumulative methadone exposure was noted in improvement period 2. Pre- and postimplementation surveys revealed that after implementation, parents had better understanding of NAS before delivery (71% vs. 100%, p = 0.009), while providers had increased comfort with outpatient management (24% vs. 67%, p < 0.001) and educating parents (48% vs. 82%, p = 0.001). CONCLUSION: This preliminary study suggests that outpatient NAS management can be safe when a comprehensive management program is implemented and can result in provider compliance with the program.
Asunto(s)
Atención Ambulatoria/organización & administración , Síndrome de Abstinencia Neonatal/terapia , Pacientes Ambulatorios , Centros Médicos Académicos , Manejo de la Enfermedad , Femenino , Adhesión a Directriz , Humanos , Recién Nacido , Masculino , Metadona/uso terapéutico , Padres/educación , Readmisión del Paciente/estadística & datos numéricos , Mejoramiento de la Calidad , Resultado del TratamientoRESUMEN
The very low birth weight (VLBW) infant is at great risk for marked dysbiosis of the gut microbiome due to multiple factors, including physiological immaturity and prenatal/postnatal influences that disrupt the development of a normal gut flora. However, little is known about the developmental succession of the microbiota in preterm infants as they grow and mature. This review provides a synthesis of our understanding of the normal development of the infant gut microbiome and contrasts this with dysbiotic development in the VLBW infant. The role of human milk in normal gut microbial development is emphasized, along with the role of the gut microbiome in immune development and gastroenteric health. Current research provides evidence that the gut microbiome interacts extensively with many physiological systems and metabolic processes in the developing infant. However, to the best of our knowledge, there are currently no studies prospectively mapping the gut microbiome of VLBW infants through early childhood. This knowledge gap must be filled to inform a healthcare system that can provide for the growth, health, and development of VLBW infants. The paper concludes with speculation about how the VLBW infants' gut microbiome might function through host-microbe interactions to contribute to the sequelae of preterm birth, including its influence on growth, development, and general health of the infant host.
RESUMEN
BACKGROUND: Antenatal MgSO4 administration is used extensively as a tocolytic agent and to treat preeclampsia. Various effects on the fetus and newborn have been reported, and MgSO4 has well-documented vasoactive effects. OBJECTIVE: To determine if antenatal MgSO4 administration affects intestinal blood flow velocity in newborn preterm infants. METHODS: Peak, mean and end-diastolic velocities in the superior mesenteric artery were measured on day 1 of life. Maternal medical records were reviewed to identify infants whose mothers had been administered MgSO4 for preterm labor or preeclampsia within 24 h of delivery. RESULT: Fifty-six infants were studied: 27 were exposed and 29 were not exposed to antenatal MgSO4. Mean birth weight (1,371 ± 349 and 1,401 ± 469 g, respectively), gestational age (29.7 ± 2.0 and 30.0 ± 2.9 weeks, respectively) and infant hemodynamic and clinical variables (other than clinical indication for antenatal MgSO4 administration) were similar between groups. There were no significant differences between the exposed and unexposed groups in intestinal blood flow velocities. For the exposed group, however, there was a significant negative correlation between mean velocity and the number of hours from birth to the time superior mesenteric artery blood flow velocity measurements were made (p = 0.002); there was no correlation for the unexposed group (p = 0.852). CONCLUSION: Group mean values indicate that antenatal exposure to MgSO4 does not significantly affect intestinal blood flow velocity in newborn preterm infants. However, the significant negative relationship between mean blood flow velocity and time from birth to blood flow velocity measurement in exposed infants suggests that there may be measurable effects of MgSO4 exposure within the hours immediately after birth. Trials that prospectively evaluate the development of intestinal blood flow velocities are needed to further clarify potential effects of antenatal MgSO4 on the gastrointestinal tract of preterm infants.
Asunto(s)
Feto/efectos de los fármacos , Recien Nacido Prematuro , Intestinos/irrigación sanguínea , Intestinos/efectos de los fármacos , Sulfato de Magnesio/farmacología , Efectos Tardíos de la Exposición Prenatal/fisiopatología , Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/farmacología , Velocidad del Flujo Sanguíneo/efectos de los fármacos , Femenino , Feto/irrigación sanguínea , Edad Gestacional , Humanos , Recién Nacido , Recien Nacido Prematuro/fisiología , Intestinos/fisiopatología , Sulfato de Magnesio/administración & dosificación , Preeclampsia/tratamiento farmacológico , Embarazo , Efectos Tardíos de la Exposición Prenatal/inducido químicamente , Tocolíticos/administración & dosificación , Tocolíticos/farmacologíaRESUMEN
Metabolic bone disease of prematurity (MBDP) is a common and significant problem that often gives rise to osteopenia, fractures, osteomalacia, and osteoporosis. The purpose of our study is to establish normative data on bone status in premature and full-term infants to help future studies on MBDP. Bone status was prospectively determined as part of a multicenter study among newborns within 96 hours of life. The patients were divided into 2 groups: group 1 included those neonates 25-36 wk gestational age (premature), and group 2 neonates were born at 37-42 wk gestational age (full term). Demographic data were collected. The Omnisense 7000 Bone Sonometer (Sunlight Medical Ltd., Tel-Aviv, Israel) was used to determine the speed of sound (SOS) through the mid tibia, which reflects bone strength. A total of 235 patients were enrolled in this study. Group 1 (i.e., the premature infants) had a statistically lower age-adjusted SOS as compared with group 2 (i.e., the full-term infants) (analysis of variance; p=0.001). There was also a correlation between SOS and birth weight (r=0.3; p<001). This study represents the largest database of normative data for bone status measuring in preterm and term infants.
Asunto(s)
Enfermedades Óseas Metabólicas/diagnóstico por imagen , Huesos/diagnóstico por imagen , Enfermedades del Prematuro/diagnóstico por imagen , Densidad Ósea , Femenino , Humanos , Recién Nacido , Recien Nacido Prematuro , Masculino , Osteoporosis/diagnóstico por imagen , Estudios Prospectivos , Valores de Referencia , UltrasonografíaRESUMEN
OBJECTIVE: To assess the tolerance of simulated amniotic fluid enterally administered in premature neonates. DESIGN: A multicentered, Phase I, dose-escalation trial was accomplished among 30 preterm neonates. Groups of 10 patients received 5, 10, or 20 mL/kg/d enterally of the amniotic fluid solution, divided into every-3-hour dosing, for 3 days. MAIN OUTCOME MEASURES: Amount and character of emesis, stools, and gastric residuals; changes in abdominal girth; presence of a skin rash; blood pressure instability; the diagnosis of necrotizing enterocolitis (NEC) or intestinal perforation. RESULTS: Thirty patients were studied: 10 received 5 mL/kg/d, 10 received 10 mL/kg/d, and 10 received 20 mL/kg/d of amniotic solution. Gestational ages ranged from 25 to 31 weeks. The Data Safety and Monitoring Board met after each group of 10 patients completed the study, reviewed the outcome measurements, and recommended continuance of the study. Dosing was discontinued for 3 patients prior to receiving all 24 doses because of gastric residuals (n = 1; 5 mL/kg), stage I NEC (n = 1; 10 mL/kg), or symptomatic patent ductus arteriosus (n = 1; 20 mL/kg). The remaining patients completed the doses with no evidence of intolerance: specifically, no increased gastric residuals, increased abdominal girth, diarrhea, blood pressure change, rash, NEC, or intestinal perforation. CONCLUSIONS: Enteral administration of an amniotic fluid-like solution to preterm neonates is well tolerated in doses Asunto(s)
Líquido Amniótico/química
, Nutrición Enteral/efectos adversos
, Fenómenos Fisiológicos Nutricionales del Lactante
, Relación Dosis-Respuesta a Droga
, Epoetina alfa
, Eritropoyetina/administración & dosificación
, Eritropoyetina/efectos adversos
, Femenino
, Filgrastim
, Hipersensibilidad a los Alimentos/etiología
, Edad Gestacional
, Factor Estimulante de Colonias de Granulocitos/administración & dosificación
, Factor Estimulante de Colonias de Granulocitos/efectos adversos
, Humanos
, Recién Nacido
, Recien Nacido Prematuro
, Masculino
, Proteínas Recombinantes